×
Insight Molecular Diagnostics EBITDA 2014-2025 | IMDX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Insight Molecular Diagnostics ebitda from 2014 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
View More
Insight Molecular Diagnostics EBITDA 2014-2025 | IMDX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Insight Molecular Diagnostics ebitda from 2014 to 2025. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company Name
Market
Cap
Veeva Systems (VEEV)
$44.5B
Doximity (DOCS)
$12.8B
Tempus AI (TEM)
$12.8B
Hims & Hers Health (HIMS)
$10B
IRhythm Technologies (IRTC)
$5.5B
Hinge Health (HNGE)
$4.5B
Inspire Medical Systems (INSP)
$2.7B
Privia Health (PRVA)
$2.7B
Heartflow (HTFL)
$2.6B
Phreesia (PHR)
$1.9B
10x Genomics (TXG)
$1.8B
Enovis (ENOV)
$1.7B
Omnicell (OMCL)
$1.5B
Schrodinger (SDGR)
$1.5B
Azenta (AZTA)
$1.4B
Clover Health Investments (CLOV)
$1.3B
Claritev (CTEV)
$1.2B
Evolent Health (EVH)
$1.1B
Fulgent Genetics (FLGT)
$674M
Zepp Health (ZEPP)
$550M
Veradigm (MDRX)
$534M
Standard BioTools (LAB)
$493M
Talkspace (TALK)
$445M
Butterfly Network (BFLY)
$410M
Carlsmed (CARL)
$363M
TruBridge (TBRG)
$300M
Health Catalyst (HCAT)
$257M
Outset Medical (OM)
$247M
SOPHiA GENETICS SA (SOPH)
$224M
Nyxoah SA (NYXH)
$214M